Publication: Pretreatment HALP score and survival outcomes in patients with metastatic renal cell carcinoma receiving first-line tyrosine kinase inhibitors: a Turkish Oncology Group Kidney Cancer Consortium (TKCC) study
Program
KU-Authors
KU Authors
Co-Authors
Günaltılı, M.
Bölek, H.
Kaplan Tüzün, E.
Usta, S.
Efil, S. C.
Akkus, A. F.
Işık, S.
Kapar, C.
Sekmek, S.
Güzel, H. G.
Editor & Affiliation
Compiler & Affiliation
Translator
Other Contributor
Date
Language
eng
Type
Embargo Status
N/A
Journal Title
Journal ISSN
Volume Title
Alternative Title
Abstract
The hemoglobin, albumin, lymphocyte, and platelet (HALP) score has been investigated as an immunonutritional biomarker in several solid tumors; however, data in metastatic renal cell carcinoma (mRCC) remain limited. This study aimed to evaluate the prognostic significance of the pretreatment HALP score in patients with mRCC receiving first-line tyrosine kinase inhibitor (TKI) therapy. Methods: A multicenter retrospective cohort study was conducted using data from the Turkish Oncology Group Kidney Cancer Consortium (TKCC) Database. HALP was calculated as hemoglobin (g/dL) × albumin (g/dL) × lymphocyte count (×109/L)/platelet count (×109/L). Patients were categorized into HALP-low and HALP-high groups according to the cohort median HALP value. Results: A total of 1001 patients were enrolled. The median time to treatment failure (TTF) was significantly shorter in the HALP-low group than in the HALP-high group (7.43 months [95% CI 6.4–8.5] vs. 14.26 months [95% CI 12.1–16.4], p
Source
Publisher
MDPI
Subject
Health sciences, Medicine, Oncology, Pulmonary and respiratory medicine
Citation
Has Part
Source
Cancers
Book Series Title
Edition
DOI
10.3390/cancers18132127